Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

• Robin Parihar,
• Stephen Gottschalk,
• Ann Leen,
• Pradip Bajgain,
• Norihiro Watanabe,
• Valentina Hoyos,
• Mary K McKenna,
• Lauren Kelly,
• Paul Shafer,
• Saisha A Nalawade,
• Arushana Ali,
• Jarrett Joubert,
• Juan Fernando Vera Valdes

Affiliations

Robin Parihar

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Stephen Gottschalk

Bone Marrow Transplant Department, St Jude Children`s Research Hospital, Memphis, Tennessee, USA

Ann Leen

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Pradip Bajgain

Mouse Cancer Genetics Program, National Cancer Institute at Frederick, Frederick, Maryland, USA

Norihiro Watanabe

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Valentina Hoyos

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Mary K McKenna

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Lauren Kelly

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Paul Shafer

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Saisha A Nalawade

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Arushana Ali

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Jarrett Joubert

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Juan Fernando Vera Valdes

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA